Physician profile
John Chan
NPI 1013178433
$3,856.10
in general payments reported to CMS, 2019-2025
33 companies · $717 in 2025
The $717 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $157 · 2021: $277 · 2022: $463 · 2023: $687 · 2024: $765 · 2025: $717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,168.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $449.53 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Ironshore Pharmaceuticals INC. | $397.05 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $346.14 | 2019-2023 | Cotempla Xr-Odt |
| Corium, LLC | $316.47 | 2022-2025 | Azstarys |
| Verrica Pharmaceuticals INC. | $303.92 | 2023-2025 | Ycanth |
| Merck Sharp & Dohme LLC | $234.11 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Tris Pharma INC | $205.72 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Collegium Pharmaceutical, INC. | $193.78 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $141.27 | 2021-2024 | Doc Band |
| Supernus Pharmaceuticals, INC. | $135.07 | 2023-2025 | Qelbree, Qelbree |
| Astrazeneca Pharmaceuticals LP | $130.40 | 2022-2024 | Flumist Quadrivalent |
| Ars Pharmaceuticals Operations, INC. | $124.99 | 2025 | Neffy |
| Kaleo, INC. | $122.26 | 2021-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $86.73 | 2019-2021 | |
| Dermira, INC. | $86.47 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $73.02 | 2024-2025 | |
| Sanofi Pasteur INC. | $67.02 | 2021-2025 | |
| Adlon Therapeutics L.P. | $49.00 | 2019-2021 | |
| Lnhc, INC | $46.41 | 2025 | Zelsuvmi |
| Noven Therapeutics, LLC | $40.53 | 2024 | Xelstrym |
| Arbor Pharmaceuticals, INC. | $38.92 | 2019 | |
| Alk-Abello, INC | $35.83 | 2025 | Odactra, Ragwitek, Grastek |
| Abbott Laboratories | $33.41 | 2025 | Freestyle Libre 3 |
| Cipher Pharmaceuticals US LLC | $29.89 | 2025 | Natroba, Spinosad |
| Vertical Pharmaceuticals, LLC | $28.48 | 2019-2025 | Relexxii |
| Sobi, INC | $26.87 | 2019-2020 | |
| Concordia Pharmaceuticals INC. | $26.16 | 2019 | |
| Avanos Medical | $22.60 | 2024 | Standard Rf Disposables |
| Shire North American Group INC | $16.32 | 2019 | |
| Pfizer INC. | $14.38 | 2021 | |
| Coastal Medical Technologies LLC | $13.41 | 2023 | |
| Rhodes Pharmaceuticals L.P. | $11.56 | 2019 | |
| Aytu Biopharma, INC. | $8.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.